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National & international granting strategies in PPPM:
innovative programmes & economy of personalised medicine
THE INNOVATIVE MEDICINES INITIATIVE -
A EUROPEAN PUBLIC-PRIVATE PARTNERSHIP
TO BOOST DRUG DEVELOPMENT
THROUGH PRECOMPETITIVE RESEARCH
Goldman M
Innovative Medicines Initiative, Brussels, Belgium
The pharmaceutical industry is developing new models
for drug development based on collaborative efforts and
precompetitive research. In order to facilitate the
implementation of these new approaches to drug
innovation across Europe, the European Union and
EFPIA (the European Federation of the Pharmaceutical
Industries and Associations) launched the Innovative
Medicines Initiative (IMI) in 2008. With a total budget
of €2 billion, IMI is the largest public-private partner-
ship (PPP) in life sciences research and development
(R&D). To fulfil its mission, IMI implements R&D
programmes focused on the development of new tools
and methods for the prediction of drug safety or
efficacy and more efficient knowledge management.
Furthermore, IMI supports education and training proj-
ects on the same topics. IMI-sponsored activities are
conducted by consortia gathering together pharmaceuti-
cal companies, small and medium-sized enterprises
(SMEs) and partners from the public sector. EFPIA
pharmaceutical companies invest in the form of ‘in
kind’ contributions, while the European Commission
provides funding to other consortium members including
academic teams, SMEs, patients’ organisations, regula-
tory agencies and other not-for-profit institutions. On the
basis of the first achievements of the 23 IMI projects
which are currently up and running, we will discuss
how precompetitive pharmaceutical research can con-
tribute to shape the future of medicine.
SYSTEMATIC, EVIDENCE-BASED DISCOVERY
OF BIOMARKERS AT THE NCI
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Translation of cancer biomarkers into clinically useful
diagnostics tests has been plagued by several discovery-
related issues, in particular, quality of samples, clinical
questions and related study designs. These issues have led
to unsatisfactory progress in the translation of biomarkers to
clinical use. Most often laboratory discoveries are made
using convenience samples and are conducted without due
consideration of intended clinical use. There have been
numerous published reports pointing out the deficiencies in
biomarker research. Over-fitting of the limited data with
fewer samples has led to unsubstantiated findings and poor
success rates.
In 2000, NCI established a network of investigators compris-
ing basic scientists, epidemiologists, clinicians, and bioinfor-
maticists to address some of the biomarkers developmental
issues. The network known as Early Detection Research
Network (EDRN; www.cancer.gov/edrn) has emerged as the
leading platform supported by the National Cancer institute
to systematically discover, develop and validate biomarkers
for identifying cancer risk, early cancer detection, and
diagnosis and prognosis of cancer.
EDRN has developed a five-phase criterion and a “go” or a
“no go”, algorithm for selecting biomarkers that are useful.
In the five phase criteria, Phase 1 includes exploratory
study to identify potentially useful biomarkers. In Phase 2,
biomarkers are studied to determine their capacity for
distinguishing between cases with cancer and those
without. Phase 2 is called the validation phase. Repositories
of longitudinally collected clinical specimens from research
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cohorts are used in Phase 3 to determine the capacity of a
biomarker to detect preclinical disease. Phase 4 consisted of
the use of prospective screening studies. Finally, large-scale
population studies that evaluate not just the role of the
biomarker for detection of cancer, but the overall impact of
screening on the population comprises phase 5.
The criteria have been further expanded, especially for
Phase II and Phase III, which include: (1) prospective
collection of samples from the target population, (2)
retrospective random sampling of cases and controls after
the outcome status is ascertained. Specimens assayed for
biomarkers, are blinded to achieve case-control status. This
design is also known as PRoBE design. The PRoBE design
has been the basis for EDRN’s efforts to collect Reference
Samples for quickly and cheaply evaluating biomarkers.
The speaker will provide examples of discovery and
validation studies based on PRoBE design and reference
samples.
INTRODUCTION TO THE ESF FORWARD LOOK
ON PERSONALISED MEDICINE
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The European Science Foundation (ESF; www.esf.org) is
an independent non-governmental organisation funded by
its Member Organisations, European funding and
performing organisations as well as scientific academies.
The ESF’s aim is to act as a catalyst for the development of
science by bringing together leading scientists and research
funding agencies to debate, plan and implement pan-
European initiatives and to explore new directions for
research at the European level.
Healthcare is on the brink of a revolution precipitated by
dramatic advances in biomedical research. The ability to
distinguish, at the molecular level, what makes one person
different from another lies at the heart of this fundamental
shift. Combined, these developments will change our
approach to medicine from finding cures towards individ-
ualised prediction, diagnosis, treatment and prevention.
Indeed, individualised biological profiles will in the future
be used to determine a person’s individual healthcare needs.
This paradigm shift has been coined as ‘personalised
medicine’.
The European Medical Research Councils (EMRC), which
is the membership organisation for all the medical research
councils in Europe under the ESF, has decided to conduct a
foresight initiative termed ‘Personalised Medicine for the
European Citizen’. This field represents an important
strategic priority area that involves not only biomedical
and technological issues, but also impinges on overarching
societal, ethical, economical and legal questions, which is
why this Forward Look is supported by all five ESF
Standing Committees.
Forward Looks are ESF strategic foresight instruments,
intended to enable Europe’s scientific community, in
interaction with policy makers, to develop medium to
long-term views and analysis of future research develop-
ments with the aim of defining research agendas at national
and European level. The present presentation will introduce
the Forward Look instrument and outline the priority areas
of this initiative.
THE ECONOMICS OF PERSONALIZED MEDICINE
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Traditional biotechnological or pharmaceutical product
development does often not appear to create financial value
when average sales figures, attrition rates, and costs are
applied to financial models of drug development [1].
Reasons are related to high attrition rates in drug develop-
ment, high development costs, and limited sales potential
due to cost-containment efforts in the healthcare sector.
Therefore, biotech companies are not anymore preferred
targets for venture capital.
Personalized medicine, apart from the benefits it offers to
patients, may raise investors’ interest again. Financial
models of personalized medicine often predict returns that
are in line with investors’ expectations who provide the
required capital. Historically, big pharma was hesitating to
adopt a personalized medicine approach as it was feared
that patient stratification would lead to dramatically
reduced market sizes. However, there is evidence that
personalized drugs, selected based on biomarkers, may
show superior effectiveness that warrants premium pric-
ing. It has become common practice in many countries to
link reimbursement to cost-effectiveness. Because of its
increased effectiveness, many new personalized medicines
can be expected to be cost-effective even when assuming
premium prices.
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Using a hypothetical case example of a highly effective
personalized renal cell cancer therapy, it was calculated
that
& Phase III development costs may be reduced by more
than 30%,
& Phase III development time may be reduced (depending
on recruitment time for a stratified patient group),
& the financial value for a personalized drug treatment
may increase by over 60% for a pharma company and
by over 50% for a biotech when one accounts for
decreased development cost and time, compared to
‘typical’ drug development,1
& the financial value may increase by more than 140% for
pharma and more than 110% for biotech if, in addition,
higher success probabilities are assumed for Phase III
and approval.2
Although cost-effective, new personalized medicines may
raise overall healthcare spending in the long-run. Society
needs to develop new compensation models to ensure that
every patient in need can benefit from new personalized
therapies.
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The introduction of biological science into the practice of
medicine at the end of the 20th century was a big
transforming event for the profession, leading to different
new medical models such as predictive, preventive, and
personalised medicine. Each of them is a rapidly
emerging field that helps us to determine the individual
risk to develop specific diseases, detect the disease’s
earliest onset, to prevent diseases or intervene early
enough to provide maximum benefit for each patient.
This contribution describes the different economic aspects
of prospectively medicine, the economic components of a
predictive, preventive and personalised health plan, and
shows how prospective care could relate to the commu-
nity in order to prevent possible collapse of healthcare
systems in the future. Further more there is an urgently
need in multidisciplinary approaches to develop innova-
tive applications of new biopharmaceutical- and diagnos-
tic technologies and to appropriate delivery models. Pilot
programmes to support prospective healthcare have
already been set in motion and European initiative, such
as EPMA, develop a new paradigm to use innovative
diagnostic models in prospective medicine. Political
support will also be needed to help for achieving rational
reimbursement between providers and payers, so that
prospective care can fulfil its promise of being the cost-
effective medical model to improve national health
systems.
1 Assumptions renal cell cancer: market size: 45,000 pts.; biomarker-positive:
9,000 pts.; price of standard therapy: $30,000.-; price of cost-effective
personalized therapy: $90,000; peak patient share: 60%, development costs:
preclinical:$8m, Ph.I:$8m, Ph.IIa:$12m, Ph.IIb:$25m, Ph.III:$90m traditional
drug development, Ph.III personalized medicine:$60 m; Ph.III duration
traditional DD: 3 years, Ph.III PM: 2 years; COGS: 8% of sales; MKTG:
$200 m close to launch, then 30% of sales; success probabilities: preclinical:
60%, Ph.I: 67%, Ph.IIa: 50%, Ph.IIb: 75%, Ph.III: 70%, approval: 80%; cost of
capital: pharma: 10%, biotech: 18%; perspective: preclinical development.
2 Assumed success probabilities: Ph.III: 80%, approval: 90%.
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